

133. Wynder EL, Goodman MT. Smoking and lung cancer: some unresolved issues. *Epidemiol Rev* 1983, 5, 177–207.
134. Black A, Pritchard JN. A comparison of the regional deposition and short term clearance of tar particulate material from cigarette smoke with that of 2.5 μ m polystyrene microspheres. *Aerosol Sci* 1984, 15, 224–227.
135. Petrakis NL, Gruenke LD, Beelen TC, Castagnoli N, Craig JC. Nicotine in breast fluid of non lactating women. *Science* 1978, 199, 303–305.
136. Pritchard JN, Back A, McAughey JJ. The physical behavior of sidestream smoke under ambient conditions. *Environ Technol Lett* 1988, 9, 545–552.
137. Manchester DK, Jacoby EH. Sensitivity of human placental monooxygenase activity to maternal smoking. *Clin Pharmacol Ther* 1981, 30, 687–692.
138. Vainio H, Partanen T. Population burden of lung cancer due to environmental tobacco smoke. *Mutation Res* 1989, 222, 137–140.
139. Wigle DT, Collishaw NE, Kirkbride J, Mao Y. Deaths in Canada from lung cancer due to involuntary smoking. *CMAJ* 1987, 136, 945–951.
140. Holman CDJ, Armstrong BK, Arias LN. *The Quantification of Drug Caused Morbidity and Mortality in Australia*. Canberra, Commonwealth Department of Community Services and Health, 1988.
141. Kawachi I, Pearce N, Jackson RT. Deaths from lung cancer and ischaemic heart disease due to passive smoking in New Zealand. *N Z Med J* 1989, 102, 337–340.
142. Fong P. The hazard of cigarette smoke to nonsmokers. *J Biol Phys* 1982, 10, 65–73.
143. Repace JL, Lowrey AH. A quantitative estimate of nonsmokers' lung cancer risk from passive smoking. *Environ Int* 1985, 11, 3–22.
144. Russell MAH, Jarvis MJ, West RJ. Use of urinary cotinine concentrations to estimate exposure and mortality from passive smoking in nonsmokers. *Br J Add* 1986, 81, 275–281.
145. Jarvis MJ. Application of biochemical intake markers to passive smoking measurement and risk estimation. *Mutat Res* 1989, 222, 101–110.
146. Byrd JC, Shapiro RS, Schiedermayer DL. Passive smoking: a review of medical and legal issues. *Am J Publ Health* 1989, 79, 209–215.
147. Woodward SD, Winstanley MH. Lung cancer and passive smoking at work: the Carrol case. *Med J Aust* 1990, 153, 682–684.
148. Chapman S, Woodward S. Australian court rules that passive smoking causes lung cancer, asthma attacks, and respiratory disease. *Br Med J* 1991, 302, 943–945.
149. Woodward A, McMichael AJ. Passive smoking and cancer risk: the nature and uses of epidemiological evidence. *Eur J Cancer* 1991, 27, 1472–1479.
150. Byrd JC. Environmental tobacco smoke. Medical and legal issues. *Med Clin N Am* 1992, 76, 377–398.
151. Lesmes GR, Donofrio KH. Passive smoking: the medical and economic issues. *Am J Med* 1992, 93 (suppl. 1A), 38S–42S.
152. Lebowitz MD. Health effects of indoor air pollutants. *Ann Rev Public Health* 1983, 4, 203–221.
153. Ernster VL. Trends in smoking, cancer risk, and cigarette promotion. Current priorities for reducing tobacco exposure. *Cancer* 1988, 62, 1702–1712.

Acknowledgements—This study was partially supported by the European Concerted Action on Passive Smoking (EUROPASS) of the Commission of the European Communities. Jean Trédaniel is supported by a grant from the Fondation pour la Recherche Médicale, France.

News

Cytogenetics and Molecular Genetics of Human Solid Tumours

The Fourth European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumours will be held in Amsterdam between 23–26 April 1994. The workshop will bring together all European groups working in the field of solid tumour genetics, including clinicians and pathologists, and the programme will include sessions on specific genetic mechanisms in tumorigenesis, technical developments in genetic analysis of human solid tumours, and particular types of tumours. For more information please contact Mrs J.M. van Dam, 4th European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumours, Congress Office - Bureau PAOG-Amsterdam, Tafelbergweg 25, 1105 BC Amsterdam, The Netherlands. Tel: (31) 20 566 4801, Fax: (31) 20 696 3228.

Thirteenth International Papillomavirus Conference

The Thirteenth International Papillomavirus Conference will be held in Amsterdam between 8–12 October 1994. Wide ranging topics will be addressed including cell transformation, viral gene expression, transcriptional control, pathogenesis (mucosal and cutaneous viral infections), immunity and diagnosis. For more information please contact Mrs Carla Schoof, Conference Sec-

retariat, Bureau PAOG Amsterdam, Tafelbergweg 25, 1105 BC Amsterdam, The Netherlands. Tel: (31) 20 566 4801, Fax: (31) 20 696 3228.

Radiotherapy Technique, Dose and Fractionation in Breast-Conserving Treatment: Current Issues

The British Institute of Radiology has organised the above meeting, which will be held on 29 October 1993. Invited speakers will include Dr J. Yarnold (London), Dr G. Ribiero, (Manchester) and Mr M. Dixon (Edinburgh). For further information please contact Miss Charlotte McLeish, BIR, Conference Office, 36 Portland Place, London W1N 4AT, U.K. Tel: 071 436 7807, Fax: 071 255 3209.

Monitoring of the Intra-Tumour Environment and Its Relationship to Therapy

The British Institute of Radiology has organised the above meeting, which will be held on 12 November 1993, and invited speakers will include Professor P. Vaupel (University of Mainz), Professor J. Griffiths (St George's Hospital, London), Dr P. Price (Hammersmith Hospital, London) and Dr N. Rowell (Oxford). For further information please contact Miss Charlotte McLeish, BIR, Conference Office, 36 Portland Place, London W1N 4AT, U.K. Tel: 071 436 7807, Fax: 071 255 3209.